Senior Leadership Team

Ahmed has an extensive background in business and corporate development, portfolio strategy, and entrepreneurial experience in the life sciences industry. Prior to joining Vicore, Ahmed was the Chief Business Officer & General Counsel of Pieris Pharmaceuticals where he played a key role in development of the company’s pipeline and execution of strategic collaborations with a range of pharmaceutical companies. Ahmed previously was an attorney representing biopharmaceutical companies in a range of matters at Covington & Burling and Kirkland & Ellis.

Shareholdings: View shareholding

Options: 2.300.000

Education: Undergraduate degrees in molecular biology and government from Cornell University and a master’s degree in biotechnology from Johns Hopkins University. Juris Doctor from Georgetown Law with honors.

Hans has a cross-disciplinary background in finance and biomedicine. He has previously worked as a biotechnology analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.

Shareholdings: View shareholding

Options: 565.000

Education: Ph.D. in Business Administration from the University of Gothenburg. After he obtained his Ph.D.-degree he conducted postdoctoral studies at the Haas School of Business at the UC Berkeley in the US. He also has a background in chemical engineering with a focus on biotechnology from Chalmers University of Technology.

Johan has more than 20 years of experience of medical science, pharmaceutical R&D and patenting from his work as physician, different roles within big and small pharma, co-founding and managing startup companies, as well as venture capital investment.

Shareholdings: View shareholding

Options: 420.000

Education: MD PhD from the Karolinska Institute and Vanderbilt university, USA

Dr. Bernt van den Blink is a board-certified pulmonologist with 25+ years academic and industry experience in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). He has extensive experience advancing global late-stage IPF programs, including at Promedior (acquired by Roche) and Galapagos, and has consulted for multiple biotech companies supporting IPF drug development. Most recently, Bernt was acting Head of Clinical Development at Kinevant, leading a global study in pulmonary sarcoidosis.

Shareholdings: –

Options: 150.000

Education: MD PhD from University of Amsterdam, The Netherlands.

Rob brings over 20 years of experience across biotech and large pharma, spanning early discovery through late-stage development. He most recently served as VP and Head of Respiratory Biology at GSK, where he led strategy and delivery for a broad respiratory portfolio. Previously, Rob held senior leadership roles at Galecto, including as Chief Scientific Officer, where he advanced assets across respiratory and liver disease.

Shareholdings: –

Options: –

Education: MPharmacol, University of Bath. PhD Pharmacology, University of Strathclyde.

Mikael has extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.

Shareholdings:View shareholding

Options: 336.000

Education: MSc Pharmacy, Uppsala University. PhD Neurobiology, Karolinska Institutet.

Helen is a pharmaceutical scientist and business leader, with over 25 years of experience delivering the technical and strategic development of novel compounds, devices and companies.

Shareholdings: View shareholding

Options: 175.000

Education: B.Sc. in Chemical and Pharmaceutical Science, University of Sunderland.

Jimmie is an experienced deal maker in the life science industry, with extensive experience in business development, corporate strategy, and financial modeling. Prior to joining Vicore, Jimmie was Senior Director, Business Development at Pieris Pharmaceuticals, where he was responsible for business development activities, and part of establishing strategic partnerships with multiple pharmaceutical companies, including AstraZeneca, Roche/Genentech, Seagen, Servier, and Boston Pharmaceuticals.

Shareholdings: View shareholding

Options: 275.000

Education: B.Sc. Bioengineering, M.Sc. Entrepreneurship & Business Design, Intellectual Capital Management from Chalmers University of Technology.

Nina has more than 20 years of experience working with HR, administration and communication in the pharmaceutical industry.

Shareholding: View shareholding
Options: 212.500
Education: Completed training in project management, PR, communication andgraphic design at, among others, Bergh’s School of Communication.

Megan brings extensive experience in formulating and executing early commercial and new product strategies, as well as developing corporate strategy and strategic messaging. Prior to joining Vicore, she served as Senior Director of Commercial and Strategy at Pieris Pharmaceuticals, where she led cross-functional teams to optimize clinical and commercial plans and developed compelling messaging for their respiratory and oncology portfolios. Megan’s background also includes her role as Vice President of Strategy and Innovation at Artisan Healthcare. There, she was responsible for advising global pharmaceutical and clinical-stage biotechnology companies on commercial and new product strategy, including franchise and brand planning, portfolio prioritization, new product positioning, and strategic communication.

Shareholdings: View shareholding

Options: 175.000

Education: BA in Cellular Neuroscience from Colgate University

Christophe Giot brings more than 20 years of leadership experience in Medical and Clinical Affairs within the pharmaceutical and medtech industries. He has held senior roles at companies including Sanofi, Bristol Myers Squibb, and Actelion. During his tenure at InterMune (later acquired by Roche), he played a key role in the launch of the first approved therapy for idiopathic pulmonary fibrosis (IPF).

Shareholdings: –

Options: 150.000

Education: MD, board-certified cardiologist, University of Brussels, Belgium

Karin has more than 20 years of experience in Regulatory Affairs within the pharmaceutical industry, inlcuding global roles at AstraZeneca, Swedish Orphan Biovitrum and Oncopeptides. She has contributed with regulatory expertise in early and late stage programs, led regulatory agency interactions as well as overseen marketing authorisation applications and post approval activities in the US, EU and rest of the world markets.

Shareholdings: –

Options: 176.250

Education: MSc Pharmacy, Uppsala University, Sweden

Anne Katrine has a MSc in Pharmacy from University of Copenhagen. During the last 20 years Anne Katrine has worked with Clinical Operations and has held various positions within clinical development in smaller and larger companies. She has been leading clinical trials from phase I to phase IV to high GCP standard and lead internal as well as external (CROs) teams. She has broad international experience and is an experienced project- and people manager.

Shareholdings: –

Options: 212.500

Education: MSc Pharmacy, University of Copenhagen, Denmark

Katrine has more than 20 years of experience in the biopharmaceutical industry, specializing in project and alliance management. She has led drug development projects with global cross-functional teams and strategic partnerships across the R&D value chain. Her previous roles include Head of Project and Alliance Management at Nykode Therapeutics and various Project Director roles at Leo Pharma, Takeda and Nycomed

Shareholdings: –

Options: –

Education: MSc Pharmacy, University of Copenhagen, Denmark

Johanna has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for drug development projects.

Shareholding: View shareholding

Options: 150.000

Education: MSc PhD

Lene has extensive experience from clinical development within pharma, biotech and CRO and has held a variety of operational, compliance, quality assurance and managerial roles. Lene is a trained ISO Lead Auditor and holds the Data Protection Officer role in Vicore. Her previous roles include individual consultancies, Global GCP QA Business Partner at LEO Pharma, VP of Quality Assurance & DPO at Larix A/S, Country Manager at Parexel Nordics and Clinical Process Manager at AstraZeneca Denmark.

Shareholding: –

Options: 62.500

Education: Registered Nurse, Master of the Psychology of Organisations from Roskilde University, Denmark

Bertil has a long career within the pharmaceutical industry with expertise within respiratory and inflammatory diseases. Bertil has held global roles within AstraZeneca, leading the development of global brands like Pulmicort and Symbicort. He was the Head of Research and Development at Almirall, leading the development of the second to market inhaled long acting antimuscarinic, aclidinium bromide. Bertil also held CMO roles in biotech companies, among others Galecto where his leadership played a crucial role in driving innovation and advancing IPF directed therapies.

Shareholdings:View shareholding

Options: 425.000

Education: MD PhD from Lund University, Sweden.

Karam Hijji is a senior legal executive with deep expertise in the pharmaceutical and life sciences industry, specializing in corporate governance, intellectual property, and transactions. He has held leadership roles at AVEO Pharmaceuticals and Pieris Pharmaceuticals, where he served as a trusted advisor to boards and executive teams, oversaw complex commercial and licensing transactions, and led legal, compliance, and data privacy programs across the US and Europe.

Shareholdings: View shareholding

Options: 175,000

Education: Doctor of Law (J.D.), Georgetown Law.
B.S. in Material Engineering, University of Maryland.

Dr. Anne Leselbaum brings over 30 years of experience in pharmaceutical and biotechnology clinical development, spanning both large-population and rare disease indications. She has held senior roles across Europe and the US, including at Ipsen, Almirall, Tigenix, Aelix Therapeutics, Alexion (AstraZeneca Rare Disease), and LFB Biomanufacturing. Her expertise spans small molecules, orphan drugs, COPD, stem cell therapies, HIV vaccines, and plasma-derived products and served as Chief Medical Officer at Bone Therapeutics. She has contributed to multiple regulatory approvals, the latest being an NDA for an orphan indication granted in 2025.

Shareholdings: View shareholding

Options: –

Education: MD from Université Paris Rene Descartes